Jazz Pharmaceuticals (NASDAQ:JAZZ) shares fell 4% after-hours today following the failure of its Phase 2 trial for JZP150, a treatment for post-traumatic stress disorder (PTSD). The trial, which evaluated the efficacy and safety of JZP150, did not meet its primary endpoint of significantly reducing PTSD symptoms.
"We plan to fully evaluate these data; however, based on top-line results we do not anticipate moving forward with additional JZP150 development in PTSD. We recognize the significant unmet need for PTSD patients and plan to share the findings from this trial with the medical community at a future date,” said Rob Iannone, executive vice president, global head of research and development of Jazz Pharmaceuticals.